Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Proteomics

  • Home
  •  
  • Proteomics



  • Most Read
  • Latest Comments
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Archer begins new experiments for its lab-on-a-chip for kidney disease detection
    Archer begins new experiments for its lab-on-a-chip for kidney disease detection
    • News

  • Proteomics signs deal with Omics Global Solutions to provide Chile with early diabetic kidney disease detection
    Proteomics signs deal with Omics Global Solutions to provide Chile with early diabetic kidney disease detection
    • News

  • Proteomics’ early detection test for endometriosis potentially a game changer
    Proteomics’ early detection test for endometriosis potentially a game changer
    • News

  • Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice
    Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice
    • News

  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • News

    Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device

    Australian medtech developer Proteomics International Laboratories (PILL, ASX: PIQ) has reached a landmark milestone having secured CE Mark certification for commericalisation of their in vitro diagnostic medical device in Europe, which can predict the early onset of diabetic kidney disease. The device, PromarkerD, takes a blood test which then creates a unique protein fingerprint which

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.